Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis

Ajithkumar, Priyadarshana; Vasantharajan, Sai Shyam; Pattison, Sharon; McCall, John L.; Rodger, Euan J.; Chatterjee, Aniruddha

doi:10.3390/ijms25020874

Cited by 3 publications

(1 citation statement)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be why ETS2 improves the prognosis of tumor patients ( 27 ). CDKN2A , also known as P16 , is currently a very common factor in tumor research, and consistent with our findings, it has been confirmed to be a poor prognostic factor in patients with CRC due to its hypermethylation ( 52 ).…”

Section: Discussionsupporting

confidence: 89%

Senescence-related signatures predict prognosis and response to immunotherapy in colon cancer

Hu,

Zhu,

Chen

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is one of the most common cancers. Cellular senescence plays a vital role in carcinogenesis by activating many pathways. In this study, we aimed to identify biomarkers for predicting the survival and recurrence of CRC through cellular senescence-related genes. Methods Utilizing The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, RNA-sequencing data and clinical information for CRC were collected. A risk model for predicting overall survival was established based on five differentially expressed genes using least absolute shrinkage and selection operator-Cox regression (LASSO-Cox regression), receiver operating characteristic (ROC), and Kaplan-Meier analyses. The study also delved into both the tumor microenvironment and the response to immunotherapy. Moreover, we gathered clinical sample data from our center in order to confirm the findings of public database analysis. Results Through ROC and Kaplan-Meier analyses, a risk model was developed using five cellular senescence-related genes [i.e., CDKN2A , SERPINE1 , SNAI1 , CXCL1 , and ETS2 ] to categorize patients into high- and low-risk groups. In the TCGA-colon adenocarcinoma (COAD) and GEO-COAD cohorts, the high-risk group was associated with a bleaker forecast (P<0.05), immune cell inactivation, and insensitivity to immunotherapy in IMvigor210 database ( http://research-pub.gene.com/IMvigor210CoreBiologies/ ). Clinical samples were then used to confirm that ETS2 and CDKN2A could serve as independent prognostic biomarkers in CRC. Conclusions Gene signatures related to cellular senescence, specifically involving CDKN2A and ETS2, are emerging as promising biomarkers for predicting CRC prognosis and guiding immunotherapy.

show abstract

Section: Discussionsupporting

confidence: 89%